Conclusions
CINV
SECONDARY
Results of this secondary analysis suggest that treating patients with 5 mg of olanzapine plus triplet antiemetic therapy from the time of initial chemotherapy is beneficial for countering CINV regardless of the presence or absence of risk factors. Moreover, the addition of olanzapine might reduce the RD by age and history of pregnancy-related illness, which are typical risk factors for CINV.